You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
格隆匯公告精選(港股)︱百度集團-SW(09888.HK)斥約21億美元收購JOYY在中國的直播業務
格隆匯 02-25 22:55

【今日焦點】

百度集團-SW(09888.HK)斥約21億美元收購JOYY在中國的直播業務

百度集團-SW(09888.HK)公告,2025年2月25日,百度與歡聚集團訂立協議並收購先前由JOYY擁有的中國內地視頻娛樂直播業務(即YY直播)。百度已支付總收購價約21億美元。作爲交易的一部分,百度之前根據股份購買協議(其後不再有效)存入託管賬戶的總金額約16億美元已悉數釋放予百度。百度計劃將有關釋放的資金投資於其雲及AI基礎設施。

【重大事項】

EDA集團控股(02505.HK)全面接入DeepSeek大模型,通過AI賦能跨境電商

伊登軟件(01147.HK):易AI助手、智繪大師、智能知識測評系統等自主研發軟體已成功接入DeepSeek-R1/V3671B滿血版

中國生物科技服務(08037.HK)與深圳華大基因簽署戰略合作框架協議

浙江滬杭甬(00576.HK)訂立高速公路幹線通道數字化場景支撐軟硬件項目合同

貝康醫療-B(02170.HK)與RheaLabs Pte. Ltd訂立戰略合作協議 攜手打造人工智能賦能的標杆性試管嬰兒(IVF)診所

華昊中天醫藥-B(02563.HK)獲納入恆生綜合指數成份股

國富創新(00290.HK)與誇密量子簽訂戰略合作協議 在量子科學領域進行深度合作

【財報業績】

新意網集團(01686.HK):中期股東應佔溢利上升11%至4.84億港元

黛麗斯國際(00333.HK)中期銷售收入上升25.0%至6.42億港元

檳傑科達(01665.HK)年度溢利達1.07億令吉 同比減少24.7%

【醫藥創新】

翰森製藥(03692.HK):B7-H3靶向抗體–藥物偶聯物HS-20093用於骨肉瘤獲國家藥品監督管理局納入突破性治療藥物

【收購出售】

天利控股集團(00117.HK)附屬斥資1.75億日圓向東榮收購機器

珠江鋼管(01938.HK)擬3025萬元出售廣東雲浮雲安區土地

【股權激勵】

阿里巴巴-SW(09988.HK)授出766.4萬股獎勵股份

【增發供股】

卓航控股(01865.HK)擬折讓約16.3%配發2833.6萬股 淨籌561.7萬港元

【回購註銷】

匯豐控股(00005.HK)2月24日耗資2.12億港元回購247萬股

波司登(03998.HK)2月25日耗資1905萬港元回購500萬股

保誠(02378.HK)2月24日耗資283.55萬英鎊回購40萬股

太古股份公司A(00019.HK)2月25日耗資1946萬港元回購30萬股

中國外運(00598.HK)2月25日耗資1789萬元回購354.3萬股A股

瑞聲科技(02018.HK)2月25日耗資1386萬港元回購29.15萬股

中遠海控(01919.HK)2月25日耗資1355.6萬元人民幣回購98萬股A股

迪生創建(00113.HK)2月25日註銷452.3萬股已回購股份

香港食品投資(00060.HK)2月24日註銷216.2萬股購回股份

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account